Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
Khanna
Dinesh
D
University of California, Los Angeles 90095, USA.
McMahon
Maureen
M
Furst
Daniel E
DE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000453:epidemiology; D001171:Arthritis, Juvenile / Q000188:drug therapy / Q000453:epidemiology; D000068800:Etanercept; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D015995:Prevalence; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept